Welcome to our dedicated page for Mangoceuticals SEC filings (Ticker: MGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the key numbers behind Mangoceuticals’ telemedicine growth often means digging through dense risk factors on pharmacy regulation, HIPAA compliance, and prescription fulfillment economics. If you have ever wondered where the company discloses its customer acquisition costs or how new men’s wellness products may trigger FDA scrutiny, you know that a single 10-K can feel overwhelming.
Our platform tackles that challenge head-on. Stock Titan delivers AI-powered summaries that turn each Mangoceuticals annual report 10-K simplified into a concise brief, flagging revenue drivers, churn metrics, and privacy safeguards. Need a quick read on the latest Mangoceuticals quarterly earnings report 10-Q filing? Real-time updates arrive the moment it hits EDGAR, complete with cash-burn trend analysis. Material announcements are no longer a mystery thanks to Mangoceuticals 8-K material events explained by our algorithms in plain language.
Follow every executive move with Mangoceuticals insider trading Form 4 transactions and Mangoceuticals Form 4 insider transactions real-time alerts. Drill deeper into Mangoceuticals proxy statement executive compensation to see how stock options align with growth milestones, or explore Mangoceuticals executive stock transactions Form 4 to identify buying and selling patterns. Trying to decode a complex filing on the fly? Type a natural question such as “understanding Mangoceuticals SEC documents with AI” and receive an instant answer that links directly to the source page.
From initial IPO paperwork to the newest Mangoceuticals earnings report filing analysis, every document is indexed, summarized, and cross-referenced. Stop scrolling through hundreds of pages—find exactly what matters, faster, with Mangoceuticals SEC filings explained simply.
Mangoceuticals, Inc. filed a Form 8-K reporting entry into a Mutual Rescission and Release Agreement with Navy Wharf, Ltd., effective July 30, 2025, terminating and rescinding the March 24, 2025 Master Distribution Agreement (MSA) that granted exclusive U.S./Canada licensing rights to Diabetinol trade dress and related IP.
Under the original MSA the Company issued 1,000,000 restricted shares to Navy Wharf and agreed to pay 10% of net sales as royalty. The Rescission Agreement provides mutual releases of obligations, requires Navy Wharf to cancel the Navy Shares, and states no material early termination penalties were incurred by the Company. Separately, on July 29, 2025 a warrant holder exercised for 198,000 shares at $1.50, raising $297,000; those shares were issued as 198,000 net shares under an exemption from registration. Exhibit 10.1 (Rescission Agreement) is filed.
Mangoceuticals has received a Notice of Effectiveness from the SEC for their Form S-3 registration statement, effective as of June 24, 2025, at 4:00 P.M. The Form S-3 (File Number: 333-288039) is a shelf registration statement that allows the company to offer and sell securities to the public.
A Form S-3 filing indicates that Mangoceuticals meets certain eligibility requirements, including being current with SEC reporting obligations. This registration enables the company to access capital markets more efficiently by allowing them to register securities for future public offerings. The effectiveness notice means the company can now proceed with securities offerings under this registration statement.
Filing highlight: Mangoceuticals, Inc. (CIK 0001938046; symbol MGRX) has received a formal Notice of Effectiveness from the U.S. Securities and Exchange Commission.
The SEC declared the company’s Form S-1 registration statement (File No. 333-287689) effective at 5:00 p.m. on June 18, 2025. This notice confirms that the registration statement has completed the Commission’s review and is now operative.
No further details—such as the size, terms, or purpose of the registered securities—were disclosed in the notice.
FAQ
What is the current stock price of Mangoceuticals (MGRX)?
What is the market cap of Mangoceuticals (MGRX)?
